Acurx Pharmaceuticals, Inc. Form DEF 14A: Definitive proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-09-01: Form DEF 14A; Period of report 2026-10-16; Description DEF 14A; Document tm262428-1_def14a.htm.
- 2025-08-04: Form DEF 14A; Period of report 2025-09-16; Description DEF 14A; Document tm2521566-2_def14a.htm.
- 2025-05-29: Form DEF 14A; Period of report 2025-07-17; Description FORM DEF 14A; Document tm252476-3_def14a.htm.
- 2024-04-29: Form DEF 14A; Period of report 2024-06-17; Description DEF 14A; Document tm242861-2_def14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-09-01 | DEF 14A | 2026-10-16 | DEF 14A | tm262428-1_def14a.htm |
| 2025-08-04 | DEF 14A | 2025-09-16 | DEF 14A | tm2521566-2_def14a.htm |
| 2025-05-29 | DEF 14A | 2025-07-17 | FORM DEF 14A | tm252476-3_def14a.htm |
| 2024-04-29 | DEF 14A | 2024-06-17 | DEF 14A | tm242861-2_def14a.htm |
| 2023-04-27 | DEF 14A | 2023-06-15 | DEF 14A | tm232131-2_def14a.htm |
| 2022-04-25 | DEF 14A | 2022-06-07 | DEF 14A | tm2212652-1_def14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |